• Asian Pacific Journal of Cancer Prevention
• /
• 제14권11호
• /
• pp.6209-6213
• /
• 2013

Well differentiated thyroid cancers (WDTC), including papillary (80%) and follicular (10%) types, are the most common endocrine cancers globally. Over the last few decades most the diagnosed cases have fallen into low risk categories. Radioactive iodine-131 (RAI) has an established role in reducing recurrence and improving the survival in high risk patients. In patients with primary tumor size <1 cm, RAI is not recommended by many thyroid societies. However, low risk WDTC has been an arena of major controversies, most importantly the role and dose of adjuvant RAI for remnant ablation to minimize chances of recurrence and improving survival. This review is an attempt to update readers about the previous and existing practice based on results of non-randomized trials and evolving trends fueled by recently published randomized studies.

• International journal of thyroidology
• /
• 제11권2호
• /
• pp.137-142
• /
• 2018

Background and Objectives: Radioactive iodine therapy (RAI) is an important treatment modality of Graves' disease (GD), but there is still not a consensus on the optimal dosage regimen. We studied the treatment success rate of different RAI doses, and examined which clinical markers were useful for determining the optimal RAI dosage for successful therapy in Korean patients. Materials and Methods: We retrospectively studied 123 patients with GD treated with RAI between 2004 and 2014 at Chonnam National University Hwasun Hospital. The responder group was defined as patients who developed hypothyroidism requiring levothyroxine replacement following RAI, regardless of the RAI dosage. Results: A total of 54 patients (43.9%) became hypothyroid after the first dose, and 31 needed two to four additional doses to achieve hypothyroidism. In the responder group as a whole (85 patients), the mean total dose of RAI was $15.5{\pm}7.0mCi$ and the mean thyroid volume (TV) was $35.4{\pm}23.4mL$. When divided into low dose (<15 mCi, n=46) and high dose (${\geq}15mCi$, n=39) responder groups, TV was significantly lower in the low-dose responder group ($25.7{\pm}11.4$ vs. $48.4{\pm}31.3$, p<0.001). The optimal cut-off TV for the low-dose responder group was <32.37 mL (sensitivity 80.9%, specificity 76.7%). Conclusion: TV had significant effects on the outcome of RAI in GD patients. The optimal fixed RAI dose for Korean GD patients with a large goiter (${\geq}33mL$) should be at least 15 mCi to achieve the best outcome.

• 한국콘텐츠학회논문지
• /
• 제11권1호
• /
• pp.236-244
• /
• 2011

성능이 저하된 IVR 장치의 지속적 사용은 환자 및 시술자의 방사선 피폭을 증가시킬 뿐 아니라, 잘못된 영상정보를 제공함으로써 환자에게 심각한 영향을 끼칠 수 있다. 따라서 이번 연구에서는 IVR장치의 성능평가를 위한 적절한 시험방법 및 검사기준을 마련하고자 하였다. IVR장치의 국내현황 및 규격을 조사하였으며, 표준팬텀을 이용하여 국내 IVR장치의 성능을 현장 측정함으로써, 국내 실정에 맞는 적절한 IVR 장치의 화질 및 성능평가 기준을 설정하였다. 장치의 기본적 성능에 관한 검사를 위해 관전압시험, 관전류 시험, 반가층 시험을 실시하며, NEMA stndard XR-21 Phantom을 표준팬텀으로 사용하여 화질 및 선량 평가를 하도록 하였다. 표준팬텀을 이용한 검사항목은 image-field geometry, spatial resolution, low-contrast iodine detectability, wire resolution, phantom entrance dose이다. 또한 매일, 매주, 1개월, 3개월, 6개월 및 1년 주기의 평가항목을 설정하였다. 장치의 성능기준은 진단용방사선안전관리 규정을 준용하여 kVp시험은 평균오차 ${\pm}10%$, mA시험은 평균오차 ${\pm}15%$, 반가층시험은 80kVp에서 최소 2.3mmAl으로 설정하였다. 표준팬텀의 검사기준은 image-field geometry에서 최소 acceptable이 나와야 하며, spatial resolution은 Image Intensifier 나 detector 크기기준으로 34-40cm은 0.8 lp/mm, 28-33cm은 1.0lp/mm, 22-27cm은 1.2 lp/mm이상이 나와야 한다. low contrast iodine detectability는 최소농도 200mg/cc 이상 보여야 하며, phantom entrance dose는 10R/min을 초과해서는 안 된다. Wire resolution은 정지 상태에서 최소 0.012인치까지 보여야 하며, 움직일 때 최소 0.022인치까지 보여야 한다.

• 대한두경부종양학회지
• /
• 제14권1호
• /
• pp.61-69
• /
• 1998

Objectives: The response rate of the radioactive iodine(RI) therapy with low dose was variable. Only a few studies reported the response and complication rate with high dose. The goal of this study was to access the ablation and complication rate after high dose of RI therapy (more than 100mCi) and to evaluate the factors affect the results. Material and Methods: During a period of 12 years, 225 patients received high dose of RI from 100 to 200mCi depending on the RI uptake in the whole body after total thyroidectomy. 100mCi of RI was given to 123 patients for ablation who showed the uptake only in the thyroid bed. 150mCi was given to another 84 patients for ablation who had uptake confined to the neck. The other 21 patients took more than 200mCi of RI because the whole body scan showed distant metastasis. Among these patients, the ablation and the complication rate was investigated. Results: Elevated level of the serum thyroglobulin(Tg) decreased less than 5ng/ml after RI therapy in all patients except two in the first group. The second group showed reduction of the serum Tg in 93%. Eighteen of the 21 patients in the third group are still alive after RI therapy. There were no fatal complications after high dose RI therapy and most of the complications were minimal and transient. The complication rate was not related with the dose of RI, age, sex, DNA flowcytometry, serum thyroglobulin level and the extent of node dissection. Conclusion: We concluded that RI therapy with high dose was very effective for thyroid ablation after operation and it also showed excellent results with minimal complications for treatment of metastatic lesions.

• 대한방사선기술학회지:방사선기술과학
• /
• 제39권4호
• /
• pp.565-570
• /
• 2016

방사성 요오드($^{131}I$) 치료는 분화성 갑상선암 환자에서 재발을 감소시키고 생존률을 증가시키나, 환자에서 방출되는 방사능으로 인하여 피폭을 야기시킬 수 있으므로 환자로부터 발생되는 방사선량률을 측정하는 것이 방사선안전관리 측면에서 중요하다. 방사성 요오드($^{131}I$) 치료시 널리 사용되는 측정기 중 전리함과 GM계수관으로 측정된 방사선량률의 감도와 측정효율을 구하였다. 방사성 요오드($^{131}I$)를 150mCi 경구투여 받은 분화성 갑상선암 환자의 상복부로부터 1 m거리에서 경과 시간에 따라 방사선량률을 측정하였다. 시간에 따른 변화를 직접적으로 비교한 결과, 고선량률에서의 감도와 측정효율은 GM계수관보다 전리함이 높게 나타났고, 통계적으로 유의하였다(p<0.05). 저선량률에서의 감도와 측정효율은 GM계수관보다 전리함이 낮게 나타났지만 통계적으로 유의한 차이를 나타내지 않았다(p>0.05). 방사성 요오드($^{131}I$) 치료시에 검 교정이 완료된 전리함과 GM계수관으로 정확하고 신속한 방사선량률을 측정하여 환자에게 설명함으로써 방사성 요오드 치료 후 퇴원하는 환자에게 환자가족 또는 주변 사람들에게 미칠 수 있는 방사선피폭을 예측하고, 불필요한 예단을 줄여줄 수 있을 것이다.

• Korean Journal of Radiology
• /
• 제23권9호
• /
• pp.854-865
• /
• 2022

Photon-counting detector (PCD) CT is a new CT technology utilizing a direct conversion X-ray detector, where incident X-ray photon energies are directly recorded as electronical signals. The design of the photon-counting detector itself facilitates improvements in spatial resolution (via smaller detector pixel design) and iodine signal (via count weighting) while still permitting multi-energy imaging. PCD-CT can eliminate electronic noise and reduce artifacts due to the use of energy thresholds. Improved dose efficiency is important for low dose CT and pediatric imaging. The ultra-high spatial resolution of PCD-CT design permits lower dose scanning for all body regions and is particularly helpful in identifying important imaging findings in thoracic and musculoskeletal CT. Improved iodine signal may be helpful for low contrast tasks in abdominal imaging. Virtual monoenergetic images and material classification will assist with numerous diagnostic tasks in abdominal, musculoskeletal, and cardiovascular imaging. Dual-source PCD-CT permits multi-energy CT images of the heart and coronary arteries at high temporal resolution. In this special review article, we review the clinical benefits of this technology across a wide variety of radiological subspecialties.

• 한국방사선학회논문지
• /
• 제17권1호
• /
• pp.1-9
• /
• 2023

전산화단층촬영조영술(computer tomography angiography, CTA)의 최적 화질을 위한 서로 다른 요오드 농도와 스캔 매개변수를 적용하여 필터 보정 역투영 (filtered back projection, FBP), 혼합형 반복재구성 (hybrid-iterative reconstruction, hybrid-IR) 및 딥러닝 재구성 (deep learning reconstruction, DLR)의 화질적 특성을 정량적으로 평가하였다. 320행 검출기 CT 스캐너에서 지름 19 cm의 원통형 물 팬텀 가장자리에 있는 다양한 요오드 농도 (1.2, 2.9, 4.9, 6.9, 10.4, 14.3, 18.4 및 25.9 mg/mL)의 팬텀을 스캔하였다. 각각의 재구성 기술을 사용하여 획득한 데이터는 노이즈 (noise), 변동 계수 (coefficient of variation, COV) 및 평균 제곱근 오차 (root mean square error, RMSE)을 통해 영상을 분석하였다. 요오드의 농도가 증가할수록 CT number 값은 증가하였지만 노이즈 변화는 특별한 특성을 보이지 않았다. 다양한 관전류 및 관전압에서 FBP, adaptive iterative dose reduction (AIDR) 3D 및 advanced intelligent clear-IQ engine (AiCE)에 대해 요오드 농도를 증가할수록 COV는 감소하였고 요오드 농도가 낮을 때는 재구성 기술 간의 COV 차이가 다소 발생하였지만, 요오드 농도가 높아짐에 따라 그 차이는 미약한 결과를 보였다. 또한, AiCE에서는 요오드 농도가 높아질수록 RMSE는 감소하지만 특정한 농도 (4.9 mg/mL) 이후에는 RMSE가 오히려 증가 되는 특성을 보여주었다. 따라서 최적의 CTA 영상 획득을 위해 재구성 기술에 따른 요오드 농도의 변화 및 다양한 관전류 및 관전압의 스캔 매개변수의 특성을 고려하여 환자 스캔을 해야 할 것이다.

• Korean Journal of Radiology
• /
• 제19권6호
• /
• pp.1119-1129
• /
• 2018

Objective: To compare the image quality of low-tube-voltage and low-iodine-concentration-contrast-medium (LVLC) computed tomography urography (CTU) with iterative reconstruction (IR) with that of conventional CTU. Materials and Methods: This prospective, multi-institutional, randomized controlled trial was performed at 16 hospitals using CT scanners from various vendors. Patients were randomly assigned to the following groups: 1) the LVLC-CTU (80 kVp and 240 mgI/mL) with IR group and 2) the conventional CTU (120 kVp and 350 mgI/mL) with filtered-back projection group. The overall diagnostic acceptability, sharpness, and noise were assessed. Additionally, the mean attenuation, signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and figure of merit (FOM) in the urinary tract were evaluated. Results: The study included 299 patients (LVLC-CTU group: 150 patients; conventional CTU group: 149 patients). The LVLC-CTU group had a significantly lower effective radiation dose ($5.73{\pm}4.04$ vs. $8.43{\pm}4.38mSv$) compared to the conventional CTU group. LVLC-CTU showed at least standard diagnostic acceptability (score ${\geq}3$), but it was non-inferior when compared to conventional CTU. The mean attenuation value, mean SNR, CNR, and FOM in all pre-defined segments of the urinary tract were significantly higher in the LVLC-CTU group than in the conventional CTU group. Conclusion: The diagnostic acceptability and quantitative image quality of LVLC-CTU with IR are not inferior to those of conventional CTU. Additionally, LVLC-CTU with IR is beneficial because both radiation exposure and total iodine load are reduced.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권3호
• /
• pp.1115-1118
• /
• 2016

Background: There is controversy about ablation efficacy of low or high doses of radioiodine-131 (RAI) in patients with differentiated thyroid cancers (DTC). The purpose of this prospective study was to determine efficacy of 30 mCi and 100 mCi of RAI to achieve successful ablation in patients with low to intermediate risk DTC. Materials and Methods: This prospective cross sectional study was conducted from April 2013 to November 2015. Inclusion criteria were patients of either gender, 18 years or older, having low to intermediate risk papillary and follicular thyroid cancers with T1-3, N0/N1/Nx but no evidence of distant metastasis. Thirty-nine patients were administered 30 mCi of RAI while 61 patients were given 100 mCi. Informed consent was acquired from all patients and counseling was done by nuclear physicians regarding benefits and possible side effects of RAI. After an average of 6 months (range 6-16 months; 2-3 weeks after thyroxin withdrawal), these patients were followed up for stimulated TSH, thyroglobulin (sTg) and thyroglobulin antibodies, ultrasound neck (U/S) and a diagnostic whole body iodine scan (WBIS) for ablation outcome. Successful ablation was concluded with stimulated Tg< 2ng/ml with negative antibodies, negative U/S and a negative diagnostic WBIS (triple negative criteria). ROC curve analysis was used to find diagnostic strength of baseline sTg to predict successful ablation. Results: Successful ablation based upon triple negative criteria was 56% in the low dose and 57% in the high dose group (non-significant difference). Based on a single criterion (follow-up sTg<2 ng/ml), values were 82% and 77% (again non-significant). The ROC curve revealed that a baseline sTg level ${\leq}7.4ng/ml$ had the highest diagnostic strength to predict successful ablation in all patients. Conclusions: We conclude that 30 mCi of RAI has similar ablation success to 100 mCi dose in patients with low to intermediate risk DTC. A baseline $sTg{\leq}7.4ng/ml$ is a strong predictor of successful ablation in all patients. Low dose RAI is safer, more cost effective and more convenient for patients and healthcare providers.

• Journal of Yeungnam Medical Science
• /
• 제40권1호
• /
• pp.12-22
• /
• 2023

Graves disease (GD) is the most common cause of hyperthyroidism, accounting for more than 90% of cases in Korea. Patients with GD are treated with any of the following: antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, or thyroidectomy. Most patients begin treatment with ATDs, and clinical guidelines suggest that the appropriate treatment period is 12 to 18 months. While RAI treatment and surgery manage thyrotoxicosis by destroying or removing thyroid tissue, ATDs control thyrotoxicosis by inhibiting thyroid hormone synthesis and preserving the thyroid gland. Although ATDs efficiently control thyrotoxicosis symptoms, they do not correct the main etiology of GD; therefore, frequent relapses can follow. Recently, a large amount of data has been collected on long-term ATDs for GD, and low-dose methimazole (MMZ) is expected to be a good option for remission. For the long-term management of recurrent GD, it is important to induce remission by evaluating the patient's drug response, stopping ATDs at an appropriate time, and actively switching to surgery or RAI therapy, if indicated. Continuing drug treatment for an extended time is now encouraged in patients with a high possibility of remission with low-dose MMZ. It is also important to pay attention to the quality of life of the patients. This review aimed to summarize the appropriate treatment methods and timing of treatment transition in patients who relapsed several times while receiving treatment for GD.